

February 2026 Medical Drug Recommendations to EBD Commissions

No	Drug	Date Considered by Commission	Treating Diagnosis	EBD Recommendation from EBRx	Cost (AWP)	Impacted members	Change	Commission Recommendation	Board of Finance Recommendation
1	Avtozma (tocilizumab-anoh)	2/3/26	<i>Cytokine release syndrome, giant cell arteritis, interstitial lung disease, kidney transplant, neuromyelitis optica</i>	Exclude	\$103.58 per mL	0	NTM to Exclude		
2	Beizray-albumin (docetaxel/albumin)	2/3/26	<i>Multiple cancers</i>	Exclude	\$79.56 per kit	0	NTM to exclude		
3	Bildyos (denosumab 60mg/mL)	2/3/26	<i>Osteoporosis, bone loss</i>	Exclude	\$1,012.80 per mL	0	NTM to exclude		
4	Bilprevda (denosumab 120mg/mL)	2/3/26	<i>Cancer, hypercalcemia of malignancy</i>	Exclude	\$1,191.53 per mL	0	NTM to exclude		
5	Keytruda Qlex (pembrolizumab-berahyaluronate-PMPH)	2/3/26	<i>Multiple cancers</i>	No EBRx restrictions	\$14,437 per 30 days (same as Keytruda IV)	0	NTM to No EBRx Restrictions		
6	Ospomyv (denosumab 60mg/mL)	2/3/26	<i>Osteoporosis, bone loss</i>	Exclude	\$1,170 per mL	0	NTM to Exclude		
7	Skyrizi (Risankizumab-RZAA)	2/3/26	<i>Psoriasis, Chron's Disease, Ulcerative Colitis</i>	Exclude	\$23,800 every 8 weeks for CD/UC, \$28,606 every 12 weeks for psoriasis	0	Cover with PA to Exclude		
8	Soliris (eculizumab)	2/3/26	<i>Organ transplant, Myasthenia gravis, atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria</i>	Exclude	\$7,827.60/300mg vial	3 (90 day grandfather)	Cover with PA to Exclude		
9	Starjemza (ustekinumab-HMNY)	2/3/26	<i>Psoriasis, Chron's disease, ulcerative colitis, HS</i>	Exclude	\$516 per 0.5mL	0	NTM to Exclude		
10	Tyruko (natalizumab)	2/3/26	<i>Relapsing MS</i>	Cover with EBRx PA	\$568.27 per mL, \$110,813 annualized	0	NTM to Cover with EBRx PA		
11	Unloxyt (cosibelimab-IPDL)	2/3/26	<i>Cutaneous squamous cell carcinoma</i>	Exclude	\$20,760 per 28 days, given until disease progression or side effects	0	NTM to Exclude		

NTM = new to market, No EBRx Restrictions = coverage will fall under health advantage policy

PA will be managed by EBRx, If no change occurs then the drug was re-reviewed by EBRx clinical committee for new data but no change in coverage